Overview

Lexapro®'s Efficacy After Dose Escalation in Remission Study

Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is the evaluation of remission rate between escitalopram 20 mg and 30 mg in patients with major depressive disorder.
Phase:
Phase 4
Details
Lead Sponsor:
Seoul National University Hospital
Collaborator:
H. Lundbeck A/S
Treatments:
Citalopram
Dexetimide